CADTH Canadian drug expert committee recommendation : indication : for the treatment of refractory carcinoid syndrome diarrhea, in combination with somatostatin analogue (SSA) therapy, in patients inadequately controlled by SSA therapy alone. Telotristat ethyl (Xermelo-Ipsen Biopharmaceuticals Canada Inc) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Language:

English

Subjects (All):

Drugs--History.

Drugs.

Physical Description:

1 online resource

Edition:

Version: Final.

Place of Publication:

Ottawa, ON : Canadian Agency for Drugs and Technologies in Health, 2019.

Summary:

The CADTH Canadian Drug Expert Committee (CDEC) recommends that telotristat ethyl not be reimbursed for the treatment of refractory carcinoid syndrome diarrhea, in combination SSA therapy, in patients inadequately controlled by SSA therapy alone. Telotristat failed to improve symptoms of importance to patients that are associated with diarrhea such as urgency and did not improve a variety of health-related quality of life subscales associated with this condition (fatigue, body image, pain, impact on finances, and social/cognitive functioning). Moreover, telotristat did not improve other symptoms associated with carcinoid syndrome, namely abdominal pain and flushing.

Notes:

Description based on publisher supplied metadata and other sources.